Intravesical therapy in the management of superficial transitional cell carcinoma of the bladder: the experience of the EORTC GU Group.
作者信息
Newling D
机构信息
Princess Royal Hospital, Hull, UK.
出版信息
Br J Cancer. 1990 Apr;61(4):497-9. doi: 10.1038/bjc.1990.112.
Abstract
摘要
相似文献
1
Intravesical therapy in the management of superficial transitional cell carcinoma of the bladder: the experience of the EORTC GU Group.膀胱内治疗浅表性膀胱移行细胞癌的管理：欧洲癌症研究与治疗组织泌尿生殖系统肿瘤协作组的经验
Br J Cancer. 1990 Apr;61(4):497-9. doi: 10.1038/bjc.1990.112.
2
Intravesical adjuvant treatment in superficial bladder cancer. A review of the question after 15 years of experience with the EORTC GU group.
Scand J Urol Nephrol Suppl. 1991;138:167-77.
3
[Conservative treatment of superficial transitional cell carcinoma of the bladder].膀胱浅表性移行细胞癌的保守治疗
Harefuah. 1995 Jan 15;128(2):104-11.
4
Intravesical therapy: does it affect the natural history of superficial bladder cancer?膀胱内灌注治疗：它会影响浅表性膀胱癌的自然病程吗？
Semin Urol. 1992 Feb;10(1):39-44.
5
Superficial transitional (Ta/T1/CIS) cell carcinoma of the bladder.
BJU Int. 2004 Jul;94(1):18-21. doi: 10.1111/j.1464-410X.2003.04894.x.
6
Intravesical therapy for bladder cancer.
Urology. 2000 Feb;55(2):161-8. doi: 10.1016/s0090-4295(99)00463-x.
7
Intravesical interferon alfa in the treatment of superficial bladder cancer.膀胱内注射干扰素α治疗浅表性膀胱癌。
Semin Oncol. 1988 Oct;15(5 Suppl 5):10-3.
8
Management of superficial transitional cell carcinoma of the bladder.膀胱浅表性移行细胞癌的管理
Semin Urol. 1993 Nov;11(4):193-204.
9
10
Contemporary management of superficial bladder cancer.浅表性膀胱癌的当代管理
Cancer Control. 2000 Jul-Aug;7(4):335-9. doi: 10.1177/107327480000700402.
引用本文的文献
1
A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9.基于EO9药理特性的一种由NQO1（NAD(P)H：醌氧化还原酶，EC 1.6.99.2）介导的膀胱癌治疗新策略。
Br J Cancer. 2001 Oct 19;85(8):1137-46. doi: 10.1054/bjoc.2001.2056.
2
The best management of superficial bladder tumours: comparing TUR alone versus TUR combined with intravesical chemotherapy modalities?浅表性膀胱肿瘤的最佳治疗方法：单纯经尿道膀胱肿瘤切除术与经尿道膀胱肿瘤切除术联合膀胱内化疗方式的比较？
Int Urol Nephrol. 2000;32(1):53-8. doi: 10.1023/a:1007199932271.
3
The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group.浅表性膀胱癌的临床流行病学。荷兰东南部泌尿外科合作组。
Br J Cancer. 1993 Apr;67(4):806-12. doi: 10.1038/bjc.1993.147.
4
BCG in the treatment of superficial cancer of the bladder: a review.卡介苗治疗浅表性膀胱癌：综述
Med Oncol Tumor Pharmacother. 1993;10(1-2):31-6. doi: 10.1007/BF02987766.
5
Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy.膀胱癌患者膀胱镜随访及辅助膀胱内化疗的变更建议
BMJ. 1994 Jan 22;308(6923):257-60. doi: 10.1136/bmj.308.6923.257.
6
Monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer.用于人类膀胱癌膀胱内放射免疫治疗的单克隆抗体。
Cell Biophys. 1993 Jan-Jun;22(1-3):27-47. doi: 10.1007/BF03033865.
7
Immunoscintigraphy with iodine-131-labelled monoclonal antibody AUA1 in patients with transitional cell carcinoma of the bladder.
Urol Res. 1994;22(5):323-7. doi: 10.1007/BF00297203.
8
Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.表柔比星。对其药效学和药代动力学特性以及在癌症化疗中的治疗应用的综述。
Drugs. 1993 May;45(5):788-856. doi: 10.2165/00003495-199345050-00011.
9
Morphological aspects of the interaction of Bacillus Calmette-Guérin with urothelial bladder cells in vivo and in vitro: relevance for antitumor activity?卡介苗与膀胱尿路上皮细胞在体内和体外相互作用的形态学方面：与抗肿瘤活性的相关性？
Urol Res. 1992;20(3):219-28. doi: 10.1007/BF00299721.
本文引用的文献
1
Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.卡介苗免疫疗法治疗浅表性膀胱癌
J Urol. 1980 Jul;124(1):38-40. doi: 10.1016/s0022-5347(17)55282-9.
2
Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.卡介苗用于浅表性膀胱癌患者的经验。
J Urol. 1982 Jul;128(1):27-30. doi: 10.1016/s0022-5347(17)52736-6.
3
Does intravesical chemotherapy prevent invasive bladder cancer?
J Urol. 1984 Jan;131(1):33-5. doi: 10.1016/s0022-5347(17)50180-9.
4
Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group.
J Urol. 1983 Apr;129(4):730-3. doi: 10.1016/s0022-5347(17)52330-7.
5
Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of a European organization for research on treatment of cancer. Randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone.浅表性移行细胞膀胱癌的辅助化疗：欧洲癌症研究与治疗组织的初步结果。比较盐酸阿霉素、环氧氯丙烷与单纯经尿道切除术的随机试验。
J Urol. 1984 Aug;132(2):258-62. doi: 10.1016/s0022-5347(17)49582-6.
6
Anaphylactic reactions to repeated intravesical instillation with cisplatin.对顺铂反复膀胱内灌注的过敏反应。
Lancet. 1983 Jun 18;1(8338):1378-9. doi: 10.1016/s0140-6736(83)92153-0.
7
Papilloma of the urinary bladder.膀胱乳头状瘤
Cancer. 1970 Feb;25(2):333-42. doi: 10.1002/1097-0142(197002)25:2<333::aid-cncr2820250209>3.0.co;2-e.
8
Benign papilloma or papillary carcinoma of the bladder?膀胱良性乳头状瘤还是乳头状癌？
J Urol. 1973 Aug;110(2):205-7. doi: 10.1016/s0022-5347(17)60161-7.
9
The management of superficial bladder tumours with intravesical Epodyl.膀胱内使用表柔比星治疗浅表性膀胱肿瘤
Br J Urol. 1973 Feb;45(1):84-7.
10
Mitomycin C in superficial bladder cancer: 24-month follow-up.丝裂霉素C治疗浅表性膀胱癌：24个月随访
Br J Urol. 1985 Dec;57(6):686-9. doi: 10.1111/j.1464-410x.1985.tb07032.x.
Zotero 插件